Plasma Exchanges in Multiple Sclerosis (MS) Relapses
Plasma Exchanges in Multiple Sclerosis (MS) Relapses
In more than 40 % of multiple sclerosis (MS) patients experiencing relapse, residual
 disability accumulates in spite of steroid treatment. Plasma exchanges are frequently used
 but there is no established evidence of their efficacy.
Multiple sclerosis (MS) relapses are usually treated by steroids but some patients did not
 respond well to this treatment. In more than 40 % of MS patients experiencing relapses,
 residual disability accumulates in spite of steroid treatment and did not recover. Plasma
 exchanges (PE) are frequently used to treat the severe attacks of inflammatory demyelination
 in the central nervous system resistant to steroids (Tumani, 2008). This strategy has been
 evaluated so far only in few studies. Only one randomized controlled study has been performed
 (Weinshenker et al, 1999) including patients with very severe attacks of inflammatory
 demyelinating diseases of various origin (MS, acute transverse myelitis, acute disseminated
 encephalomyelitis, neuromyelitis optica), not improved after a treatment by steroids. A
 moderate or important improvement of incapacity was observed in 8 cases out of 19 (42.1%)
 after treatment by PE against 1 out of 17 (5.9%) after sham treatment. This study concerned
 only 12 patients having a relapse of MS. Based on this first controlled study and the
 experience of treatment of 42 MS patients in the department of Neurology of the University
 Hospital Pellegrin (CHU de Bordeaux) we designed a randomized controlled study of PE against
 sham PE in moderate to severe acute exacerbations of MS not responding to steroid treatment.

 The purpose is to compare plasma exchanges versus sham exchanges on residual disability in MS
 patients with a demyelinating inflammatory episode (MS or syndrome with high risk of MS)
 experiencing a disabling relapse not improved after steroid treatment. The primary end-point
 will be evaluated one month after start of therapy. Secondary endpoints include safety and
 evaluation of improvement at 3 and 6 months and evaluation of safety
Inclusion Criteria:

 -  Probable relapsing-remitting MS (RRMS) according to Polman et al criteria 2010. or
 clinically isolated neurological syndrome (CIS) compatible with a demyelinating
 inflammatory episode within the central nervous system, potentially beginning multiple
 sclerosis (MS).

 -  Age 18-65

 -  EDSS before the current relapse <6.5

 -  Acute relapse (optic neuritis, motor pyramidal relapse, cerebellar relapse, oculomotor
 relapse) since less than 2 months

 -  Having been treated by IV or orally steroid (Methylprednisolone, 1g/d for at least 3
 days), followed or not by oral tapering.

 -  The current relapse inducing a significant clinical deterioration as compared to
 pre-relapse status and persisting 30 days after starting steroids.

 -  Loss of visual acuity more than 30% on one ot both eyes;

 -  Or: increase of 1 point pyramidal or brainstem functional system score (FSS) (if
 score ≥ 3) or cerebellar FSS (if score ≥ 2).

 -  Or: reduced walking distance associated with an increase ≥ 0.5 point EDSS if EDSS
 ≥4.0;

 -  Having signed informed consent.

 -  affiliated to the French Social Security

 Exclusion Criteria:

 -  Infection

 -  Improving relapse.

 -  Other disease interfering with evaluation.

 -  Current treatment by immunosuppressive drug (as cyclophosphamide and mitoxantrone) or
 interrupted for less than 3 months.

 -  Modification of DMT since less than 1 month.

 -  Physical or psychic disease interfering with evaluation or consent.

 -  Participation to another trial in the last 3 months.

 -  Inability to establish peripheral central intravenous access;

 -  Cerebral, autonomic, cardiac or other conditions with increased risk from hypovolemia

 -  Pregnancy or breast-feeding.

 -  Woman in age to procreate without effective contraception

 -  Treatment by monoclonal antibody.

 -  Progressive course of MS.